Merck Wins Part D Cholesterol Therapy Formulary Battle; Lipitor In Retreat?
Executive Summary
Merck appears to be the big winner in the Medicare Part D formulary placement battle for cholesterol-lowering therapies, according to an analysis of plan formularies conducted by the "The Pink Sheet."
You may also be interested in...
Zocor Falls Off Formularies As Part D Plans Shift Patients To Generic Statins
Zocor dropped quickly off of Part D formularies after having enjoyed wide preferred coverage in 2006, an analysis of 2007 Part D basic plan coverage of the statin group of cholesterol-lowering drugs indicates
Zocor Falls Off Formularies As Part D Plans Shift Patients To Generic Statins
Zocor dropped quickly off of Part D formularies after having enjoyed wide preferred coverage in 2006, an analysis of 2007 Part D basic plan coverage of the statin group of cholesterol-lowering drugs indicates
Amgen Head-To-Head R&D Strategy Speaks To Growing Importance Of Payers
Amgen's strategy of conducting head-to-head trials of its products against current standards of care pre-approval indicates the firm is focusing on effectively positioning products in an increasingly competitive, Medicare-oriented reimbursement environment